A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.

Trial Profile

A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2015

At a glance

  • Drugs GSK 945237; Linezolid; Moxifloxacin
  • Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Bacterial infections; Community-acquired pneumonia; Gram-positive infections; Intra-abdominal infections; Methicillin-resistant Staphylococcus aureus infections; Nosocomial pneumonia; Skin and soft tissue infections; Tuberculosis; Vancomycin-resistant enterococcal infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 21 Apr 2015 Status changed from discontinued to withdrawn prior to enrolment as per ClinicalTrials.gov record.
    • 13 May 2011 Planned end date changed from 1 Jul 2010 to 1 Aug 2010 as reported by ClinicalTrials.gov.
    • 13 May 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top